## First-Line Agent in Type 2 Diabetes **Key Point:** Metformin is the universally recommended first-line pharmacological agent for type 2 diabetes mellitus in patients with normal renal function, regardless of BMI or comorbidities. ### Rationale for Metformin as DOC 1. **Mechanism of Action** - Decreases hepatic glucose production (primary effect) - Improves peripheral insulin sensitivity - Does NOT cause hypoglycemia as monotherapy 2. **Cardiovascular & Metabolic Benefits** - Weight neutral or modest weight loss - Improves lipid profile - Reduces cardiovascular mortality (landmark UKPDS trial) - Lowers lactate and improves insulin sensitivity 3. **Safety Profile** - Well-tolerated with minimal adverse effects - No hypoglycemia risk when used alone - Contraindicated only in severe renal impairment (eGFR <30) or acute illness - GI side effects (diarrhea, nausea) are dose-dependent and transient **High-Yield:** Metformin is recommended as first-line monotherapy by ADA, EASD, and Indian guidelines (RSSDI) for all newly diagnosed type 2 diabetics with adequate renal function. **Clinical Pearl:** The patient's normal renal function (eGFR 92) and absence of contraindications make metformin the clear choice. Start at 500 mg daily and titrate to 1500–2000 mg/day in divided doses. ### Why Metformin Wins Over Alternatives | Feature | Metformin | Glibenclamide | Pioglitazone | Acarbose | |---------|-----------|---------------|--------------|----------| | **First-line?** | Yes | No | No | No | | **Hypoglycemia risk** | None | High | Low | None | | **Weight effect** | Neutral/loss | Weight gain | Weight gain | Neutral | | **CV benefit** | Yes (UKPDS) | Neutral/harm | Neutral | Minimal | | **Renal safety** | Caution <30 | Safe | Safe | Caution <30 | | **GI side effects** | Common initially | Rare | Rare | Common | [cite:Harrison 21e Ch 417]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.